Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
08:45am, Sunday, 26'th Mar 2023
Embecta should benefit from the greater need for diabetic services. Viatris is focusing on finding new generics.
Is Viatris' 5% Dividend Yield Safe?
09:32am, Tuesday, 21'st Mar 2023
Viatris has been paying down debt, but investors remain wary of investing in the company. Interest costs, however, haven't been crippling the business.
Better Generics Pharmaceutical Stock: Teva or Viatris?
11:28am, Sunday, 05'th Mar 2023
Teva is the world's largest maker of generic drugs. Viatris offers an above-average dividend yield.
Viatris: Too Cheap To Ignore
08:05am, Wednesday, 01'st Mar 2023
Viatris recently closed out 2022 having largely met management's prior guidance. It's aggressively paying down debt and recent acquisitions may drive meaningful growth down the road.
Viatris' (VTRS) Q4 Earnings In-Line, Revenues Miss Estimates
02:18pm, Monday, 27'th Feb 2023
Viatris (VTRS) reports in-line Q4 earnings but misses on sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
12:03pm, Monday, 27'th Feb 2023
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compar
VTRS Stock Alert: What to Know as Viatris Appoints New CEO
11:18am, Monday, 27'th Feb 2023
Viatris (NASDAQ: VTRS ) stock is in the news Monday after the healthcare company announced Scott Smith as its next CEO. This will see Smith take over as the next CEO of Viatris on April 1, 2023.
Viatris (VTRS) Matches Q4 Earnings Estimates
09:02am, Monday, 27'th Feb 2023
Viatris (VTRS) delivered earnings and revenue surprises of 0% and 2.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
06:01pm, Wednesday, 22'nd Feb 2023
Dear Investor:
What To Expect From Viatris In 2023
01:45pm, Wednesday, 22'nd Feb 2023
Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish fi
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
08:14am, Saturday, 18'th Feb 2023
These pharmaceutical stocks probably won't stay so attractively valued for too much longer.
Competition Coming For AbbVie's Blockbuster Humira
01:08am, Thursday, 16'th Feb 2023
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
Don't Buy Viatris And Organon Just Because Of The Dividends
09:27am, Monday, 13'th Feb 2023
Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies
2 Superb Dividend Stocks to Buy Today and Hold Forever
05:36am, Tuesday, 24'th Jan 2023
These two companies have long runways for growth and decent yields today.
Viatris: Where Is The Cure?
02:46am, Monday, 23'rd Jan 2023
Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further.
